NRBO vs. PYRGF, HOOK, IOBT, BRNS, SPRO, ANVS, EPRX, CUE, VACC, and TPST
Should you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include PyroGenesis Canada (PYRGF), Hookipa Pharma (HOOK), IO Biotech (IOBT), Barinthus Biotherapeutics (BRNS), Spero Therapeutics (SPRO), Annovis Bio (ANVS), Eupraxia Pharmaceuticals (EPRX), Cue Biopharma (CUE), Vaccitech (VACC), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
In the previous week, PyroGenesis Canada had 2 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 2 mentions for PyroGenesis Canada and 0 mentions for NeuroBo Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.50 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that PyroGenesis Canada is being referred to more favorably in the news media.
NeuroBo Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 154.45%. Given NeuroBo Pharmaceuticals' higher probable upside, research analysts plainly believe NeuroBo Pharmaceuticals is more favorable than PyroGenesis Canada.
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than PyroGenesis Canada.
1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -201.83%. NeuroBo Pharmaceuticals' return on equity of -90.22% beat PyroGenesis Canada's return on equity.
NeuroBo Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
NeuroBo Pharmaceuticals received 27 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
Summary
NeuroBo Pharmaceuticals beats PyroGenesis Canada on 8 of the 13 factors compared between the two stocks.
Get NeuroBo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroBo Pharmaceuticals Competitors List
Related Companies and Tools
